Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Neutral 60.6%

Neg 0% Neu 60.6% Pos 0%

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.